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A B S T R A C T
Oxysterols are known pleiotropic molecules whose antiviral action has been recently discovered. Here reported
is the activity of a panel of oxysterols against HSV-1 with the identification of a new mechanism of action. A
marked antiviral activity not only of 25HC but also of 27HC against HSV-1 was observed either if the oxysterols
were added before or after infection, suggesting an activity unrelated to the viral entry inhibition as proposed by
previous literature. Therefore, the relation between the pro-inflammatory activity of oxysterols and the
activation of NF-kB and IL-6 induced by HSV-1 in the host cell was investigated. Indeed, cell pre-incubation
with oxysterols further potentiated IL-6 production as induced by HSV-1 infection with a consequent boost of the
interleukin's total cell secretion. Further, a direct antiviral effect of IL-6 administration to HSV-1 infected cells
was demonstrated, disclosing an additional mechanism of antiviral action by both 25HC and 27HC.
1. Introduction
Oxysterols are a family of cholesterol oxidation derivatives contain-
ing an additional hydroxyl, epoxide or ketone group as to the parental
compound. Due to their chemical structure, oxysterols have been
consistently demonstrated as more reactive than unoxidized cholester-
ol, being easily diffusible through cell membranes, and possessing
remarkable pro-inflammatory and cytotoxic effects in a number of cells
and tissues [1].
The biological role of oxysterols has been reconsidered for their
fundamental activity as physiological ligands of liver X receptors
(LXRs), a feedback regulating system for cholesterol homeostasis,
immune and inflammatory reactions. The oxysterols showing a high
affinity for LXRs are essentially those originated enzymatically, mainly
25-hydroxycholesterol (25HC), 27-hydroxycholesterol (27HC) and 24-
hydroxycholesterol (24HC) [2]. These oxysterols have been shown to
activate either LXR-dependent or LXR-independent cell signaling path-
ways, suggesting their dual effects as anti- or pro-inflammatory
molecules [3].
Of interest, oxysterols have recently been reported to exert antiviral
activity against different enveloped and non-enveloped viruses [4–7].
Notably, the large majority of these studies were focused on 25HC,
because the antiviral molecule interferon (IFN) proved to induce the
transcription of cholesterol-25-hydroxylase (CH25H), the enzyme re-
sponsible for 25HC synthesis [4]. Indeed, also other oxysterols are
endowed with antiviral activity, in particular side chain oxysterols.
27HC was shown to be active against murine cytomegalovirus [5],
human papillomavirus, rotavirus and rhinovirus [6]. 24HC and 25-
epoxycholesterol inhibited the growth of MCMV [5], while 22(S)-
hydroxycholesterol and 20α-hydroxycholesterol were active against
HBV [8].
If, on one hand, the broad antiviral activity of at least certain
oxysterols is nowadays well demonstrated and supported by a still
growing bulk of experimental evidence, on the other hand, the
mechanisms underlying such an important property of different cho-
lesterol oxidation products mostly remain to be elucidated (for an
updated review see 7).
A suitable approach for understanding the antiviral effects of
oxysterols, in our opinion, should be guided by the awareness that
most viral infections induce in the host the activation of innate and
acquired immune systems and trigger an inflammatory response. Of
note, most of the oxysterols of pathophysiological interest are provided
with a marked and wide pro-inflammatory effect [9–11]. In addition, at
least with regard to 25HC, solid data are available that support its
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significant involvement in the regulation of immunologic response
[12]. Hence, an oxysterol-mediated modulation of immune and flogistic
reactions of the infected host appears very likely.
Out of the several viruses whose growth resulted to be inhibited by
25HC, herpes simplex-1 (HSV-1) appeared the most affected one, at
least under the experimental conditions adopted [5]. Moreover, a
number of reports have outlined an important role played by inflam-
mation against HSV-1 infection. Indeed, an induction of pro-inflamma-
tory cytokines, in particular IL-6, in response to HSV-1 infection was
observed in different types of cells including leukocytes [13], EMT-6
epithelial cells, HaCat cells [14,15], cornea epithelial cells, fibroblasts
[16], astrocytes [4]. HSV-1-induced up-regulation of IL-6 expression
and synthesis was confirmed to be operated through the increase of Toll
Like Receptor 3 (TLR3) and Nuclear Factor kappaB (NF-kB) protein
levels [4]. The pro-inflammatory burst activated by HSV-1 infection
was proved to have an antiviral effect, by the net enhancement of viral
growth achieved every time the overproduction of IL-6 and other pro-
inflammatory cytokines was quenched or inhibited [17,18]. In this
regard, it is noteworthy the very strong enhancement of morbidity,
symptoms severity and mortality following HSV-1 respiratory infection
in knockout mice deficient for IL-6 [19].
On these bases, we deemed important to investigate the possible
anti-HSV-1 effect of a panel of oxysterols, some of them already shown
as provided with broad antiviral activity [6] and all being recognized to
induce inflammatory cytokines, including IL-6 [20,21]. The results
obtained, demonstrate that mainly 25HC and 27HC markedly inhibit
HSV-1 replication and point to the oxysterol-dependent further induc-
tion of NF-kB nuclear translocation and IL-6 production in the infected
cells as a contributing mechanism to their antiviral properties.
2. Materials and methods
2.1. Cell lines and virus
African green monkey kidney cells (Vero) (ATCC CCL-81) were
cultured in Eagle's minimal essential medium (MEM) (Gibco/BRL,
Gaithersburg, MD) supplemented with heat-inactivated 10% foetal calf
serum (FCS) (Gibco/BRL) and 1% antibiotic-antimycotic solution (Zell
Shield, Minerva Biolabs GmbH, Berlin, Germany), at 37 °C in an
atmosphere of 5% of CO2. Human epithelial adenocarcinoma HeLa
cells (ATCC® CCL-2™) were propagated in Dulbecco's modified Eagle's
medium (DMEM) (Gibco-BRL, Gaithersburg, MD) supplemented with
heat-inactivated 10% fetal bovine serum (FBS) (Gibco-BRL) and 1%
antibiotic-antimycotic solution (Zell Shield, Minerva Biolabs GmbH,
Berlin, Germany), at 37 °C in an atmosphere of 5% of CO2. Clinical
isolates of HSV-1 were kindly provided by Prof. M. Pistello, University
of Pisa, Italy. Viral strains were propagated and titrated by plaque assay
on Vero cells.
2.2. Cell viability assay
Vero and HeLa cells were seeded into 96-well plates at a density of
104 cells/well, and incubated at 37 °C in a 5% CO2 atmosphere for 24 h.
Oxysterols dissolved in ethanol (25 hydroxycholesterol 25HC, 27
hydroxycholesterol 27-HC, 7α hydroxycholesterol 7αHC, 7β hydroxy-
cholesterol 7βHC and 7Ketocholesterol 7KC) were added to the cells at
different concentrations ranging between 150 µM and 0.1 µM, with a
replicate number of three wells per concentration. 25-HC was pur-
chased from Sigma Aldrich (Saint Louis, Missouri, USA); 7αHC, 7βHC,
7KC and 27-HC were purchased from Avanti Polar Lipid (Alabaster,
Alabama). After 24 or 48 h incubation period, cell viability was
measured by the MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay by the Cell
Titer 96 Proliferation Assay Kit (Promega, Madison, WI,USA) according
to the manufacturer's instructions. Absorbance was measured using a
Microplate Reader (Model 680, BIORAD) at 490 nm. The percent of
viability was calculated in comparison with cells treated with equal
volumes of ethanol. The 50% cytotoxic concentrations (CC50) and 95%
confidence intervals (CI) were determined using GraphPad PRISM
software (Graph-Pad Software, San Diego, CA).
2.3. HSV-1 antiviral assays
Inhibition of HSV-1 replication was evaluated with plaque reduction
assay and virus yield reduction assay. Vero cells were seeded in 24-well
plates at a density of 9×104 cells. The plaque reduction assay was
performed pre-treating cells for 16 h with each oxysterol and subse-
quently infecting cell monolayers with HSV-1 at a multiplicity of
infection (MOI) of 0.0004 pfu/cell for 2 h at 37 °C. The inocula were
subsequently removed from the wells, and the cells were washed with
medium twice and overlaid with a medium containing 1.2% methyl-
cellulose (Sigma). Treatment of control samples with equal volumes of
ethanol was performed in order to rule out the possibility of any
cytotoxic or antiviral effect ascribable to the solvent. After further
incubation for 48 h at 37 °C in 5% CO2, the supernatant was removed,
and the cells were fixed and stained with 0.1% crystal violet in 20%
ethanol and viral plaques were counted. The plaques were visualized
using a Leica inverted Microscope equipped with a Bresser MikroCam
microscope camera and MikroCamLab software (Rhede, Germany).
ImageJ software was used to quantify plaque sizes. Ethanol treated
HSV-infected monolayers were used as internal control.
For the virus yield reduction assay, cells were pre-treated for 16 h
with oxysterols and infected in duplicate with HSV-1 at a MOI of 0.01
pfu/cell. Following virus adsorption (2 h at 37 °C), the virus inoculum
was removed and cells were incubated until control cultures displayed
extensive cytopathology. Alternatively, cells were infected with HSV-1
at a MOI of 0.01 pfu/cell for 2 h and subsequently incubated with
medium containing serial dilutions of oxysterols until control cultures
displayed extensive cytopathology. Supernatants were pooled as appro-
priate 48 h after infection and cell-free virus infectivity titers were
determined in duplicate by the plaque assay in Vero cell monolayers.
2.4. Oxysterols intracellular quantification
To a screw-capped vial sealed with a Teflon septum, cellular pellets
resuspended in NaCl 0.9% were added together with 2500 ng of D6-25-
hydroxycholesterol and 2500 ng of 27-hydroxycholesterol as internal
standards, 50 μl of butylated hydroxytoluene (5 g/l) and 50 μl of K3-
EDTA (10 g/l) to prevent auto-oxidation. Each vial was flushed with
argon for 20 min to remove air.
Alkaline hydrolysis was allowed to proceed at room temperature
(22 °C) with magnetic stirring for 30 min in the presence of ethanolic
1 M potassium hydroxide solution. After hydrolysis, the sterols were
extracted twice with 5 ml cyclohexane and oxysterols were eluted on
SPE cartridge by isopropanol: hexane 30:70 v/v. The organic solvents
were evaporated under a gentle stream of argon and converted into
trimethylsilyl ethers with BSTFA.
Gas chromatography mass spectrometry (GC-MS) analysis was
performed on a GC equipped with an Elite column
(30 m×0.32 mmid×0.25 mm film; Perkin Elmer, USA) and injection
was performed in splitless mode and using helium (1 ml/min) as a
carrier gas. The temperature program was as follows: initial tempera-
ture of 180 °C was held for 1 min, followed by a linear ramp of 20 °C/
min to 270 °C, and then a linear ramp of 5 °C/min to 290 °C, which was
held for 10 min.
The mass spectrometer operated in the selected ion-monitoring
mode. Peak integration was performed manually, and sterols were
quantified from selected-ion monitoring analysis against internal
standards using standard curves for the listed sterols. Additional
qualifier (characteristic fragment ions) ions were used for structural
identification. Interassay CV was 4.6% for of 25-hydroxycholesterol and
3.8% for 27-hydroxycholesterol. Recovery ranged from 98 up to 103%.
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2.5. IL-6 quantification by Elisa
HeLa cells were plated in flasks at a density of 1.2×106 cells and the
day after 25HC or 27HC were added to the incubation medium to reach
5 μM final concentration. In the control samples, the oxysterol was
replaced by equal volumes of ethanol. The following day the medium
containing oxysterols was removed, cells washed and infected with
HSV-1 at MOI of 1pfu/cell. After 24 h, cell medium was harvested and
used for ELISA analyses.
Levels of IL-6 were quantified using Human IL-6 ELISA kit
(Peprotech, Rocky Hill, NJ, USA) following the manufacturer's instruc-
tions. Sample absorbance values were read at 450 nm with a wave-
length correction of 550 nm in a microplate reader (Model 680
microplate reader Bio-Rad), and data analyzed using Slide Write Plus
software (Advanced Graphics Software). Extracellular IL-6 levels were
evaluated in triplicate and values were expressed in molarity.
2.6. Immunofluorescence
To test the localization of NF-kB, Vero cells were grown directly
onto glass coverslips in 24-well plates at a density of 9×104 cells,
treated with 25HC or 27HC for 16 h and infected with HSV-1 for 2 h at
37 °C. 24 hpi cell samples were fixed in 95% ethanol for 5 min,
permeabilized with MSM-PIPES [5 mM PIPES, 18 mM MgSO4, 5 mM
CaCl2, 40 mM KCl, 24 mM NaCl, 0.5% Triton X-100 (v:v), 0.5% Igepal
CA-630 (v:v)] for 2 min at room temperature and incubated in a
100 mM sodium cyanoborohydride reducing agent for 10 min at
37 °C. In order to block nonspecific binding, coverslips were preincu-
bated with 3% BSA in 0.01 M PBS (w:v) containing 5% normal goat
serum (v:v) and 0.3% Tween-20 (v:v) for 30 min at room temperature.
Further, slides were incubated in the presence of 1:150 dilution purified
rabbit anti-p65 monoclonal primary antibody (NF-κB p65 (D14E12)
XP® Rabbit mAb #8242, Cell Signaling Technology, Inc.). After 90 min
of incubation at room temperature in a humidified chamber specimens
were then incubated with a purified goat anti-rabbit fluorescein
isothiocyanate (FITC)-conjugated secondary antibody (Alexa Fluor,
Molecular Probes, Life Technologies) (1:300 dilution) at room tem-
perature for 60 min.
Slides were sealed with glycerol after three additional washes with
0.1 M PBS for 5 min, and observed with a confocal microscope Zeiss
LSM 510 (plan neofluar lens 20×/0.5). The instrument was set to
488 nm exciting laser band, with a 505–530 nm band pass emission
filter, to detect green fluorescence. Exciting light intensity, black level,
and photomultiplier gain were adjusted on control specimens; settings
were maintained the same when scanning experimental samples. All
images were processed using LSM 510 Image Examiner software (Zeiss
S.p.A Arese, Milan, Italy).
2.7. IL-6 antiviral assay
HeLa cells were plated in 24 wells plate at a density of 9×104 cells/
well, the following day HSV-1 at MOI 1pfu/cell was added on cells for
2 h. Following virus adsorption, the viral inoculum was removed and
cells were overlaid with medium containing IL-6 at final concentration
of 100 nM, 50 nM and 20 nM. 24 h later, supernatants and cells were
harvested and subsequently titrated on Vero cells. The percent infection
was calculated comparing viral titers in treated samples with untreated
ones. One way ANOVA was performed to reveal significant reduction of
viral titers.
2.8. Statistics
The 50% effective concentrations (EC50) and 95% confidence
intervals (CI) were determined using GraphPad PRISM software
(Graph-Pad Software, San Diego, CA).
Values of p<0.05 were considered indicative of statistical differ-
ences. * p< 0.05 **p< 0.01 ***p< 0.005 Results represent the
mean± SEM of three independent experiments. With the exception of
ELISA experiments, where data are means of four experiments± SD.
3. Results
3.1. Antiviral activity of oxysterols against HSV-1
In order to test the anti-HSV-1 activity of a panel of oxysterols of
pathophysiological relevance, an inhibition assay was performed, in
which the single 25HC, 27HC, 7αHC, 7βHC, 7KC or unoxidized
cholesterol were added to Vero cells (see Methods), at different final
concentrations, 16 h before viral infection. Experimental conditions
were those previously adopted to test the effect of the same oxysterols
on naked viruses [6], and the infection was evaluated by means of
plaque assay (see Methods). To exclude the possibility that an antiviral
activity might depend on oxysterols’ cytotoxic effects, a cell viability
assay was also performed on uninfected cells, challenged with the
tested molecules under the same experimental conditions. As reported
in Table 1, 25HC and 27HC were the only oxysterols affording a dose-
dependent decrease in plaque number, thus an antiviral effect. The CC50
and SI values indicate that the antiviral activity exerted by 25HC and
27HC was not due to cytotoxicity.
Of note, a significant reduction of plaque size was observed even
with those oxysterols whose EC50 was unmeasurable, when, according
to Blanc et al. [5], a fixed dose of 5 μM of challenging compound was
applied in a plaque reduction assay (Fig. 1, panel A). Since a reduced
plaque area may result in a decreased production of virus progeny, even
if the overall plaque number was not significantly reduced, oxysterols’
inhibitory activity was analyzed by viral yield reduction assay. This is a
more stringent test which allows multiple cycles of viral replication to
occur before measuring the production of infectious viruses. To this
aim, each oxysterol (5 μM) was added 16 h before viral inoculum (pre-
treatment) (Fig. 1, panel B) or immediately after HSV-1 infection
(treatment) (Fig. 1, panel C). 25HC and 27HC proved to be the most
potent inhibitors of HSV-1 replication, but also 7αHC, 7βHC and 7KC
significantly reduced viral yield in both the experimental conditions
adopted.
The viral yield reduction ability of 25HC and 27HC in post
treatment assays was further investigated in a dose-response manner
and the relative EC50 determined in two cell lines, namely Vero and
HeLa cells. As shown in Table 2, the two compounds were active on
both cell lines showing EC50s much lower than those determined in the
plaque assay.
3.2. Kinetics of the uptake of 25HC and 27HC by HeLa cells
Cell internalization of the two most powerful oxysterols, in terms of
antiviral activity, was evaluated using HeLa cell cultures at various time
points and different concentrations, namely from 0.2µM to 16 µM.
Notably, the amount of the two oxysterols recovered within so treated
cells, quantified by a mass spectrometry method, resulted to be
consistently lower than that added and actually recovered in the total
Table 1
Anti-HSV-1 activity and cellular toxicity of oxysterols.
Compound EC50 (µM) – 95% C.I. CC50 (µM) SI
25HC 5.06 (3.47–7.38) 77.59 15.3
27HC 17.1 (10.2–30.1) >150 >8.78
7αHC n.a. 131 n.a.
7βHC n.a. 25.03 n.a.
7KC n.a. 79.06 n.a.
Cholesterol n.a. > 150 n.a.
EC50: half maximal effective concentration; C.I. confidence interval; CC50: half maximal
cytotoxic concentration; SI: selectivity index; n.a.: not assessable.
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cell suspension (cell+incubation medium) at all the time points
considered. Indeed, 25HC cell uptake, taken as % intracellular recov-
ery, ranged from 13% to 24% of total added oxysterol, showing the
higher percent values at 16.7 µM oxysterol concentration; notably,
25HC intracellular concentration tended to decrease with time, as
evident after 72 and 96 h incubation in all but one experimental
conditions (Fig. 2). With regard to the percent amount of 27HC
recovered in the cells, values were steadily lower than those observed
for 25HC, ranging from 9% to 15% of total added oxysterol. Also 27HC
intracellular content showed to gradually decrease with time. In this
case, however, the addition of the high oxysterol amount to cell
suspension did not appear to efficiently accumulate 27HC within cells
(Fig. 2).
3.3. Pretreatment with 25HC or 27HC additionally up-regulates IL-6
secretion by HeLa cells as induced by HSV-1 infection
As reported in Fig. 3, HeLa cells infection with HSV-1 led per se to a
significant stimulation of the cytokine IL-6 secretion into the incubation
medium. A consistent increment of IL-6 extracellular levels was also
achieved when cells were 24 h pretreated with 25HC and, in particular,
with 27HC. Importantly, cell pre-incubation with oxysterols followed
by 24 h HSV-1 infection led to a significant further increase of IL-6 total
secretion, most likely because of an additive effect of the two agents.
3.4. 25HC and 27HC further enhance NF-kB activation induced by HSV-1
infection
On the basis of the unanimously recognized key role of the
Fig. 1. Plaque (A) and viral yield (B-C) reduction exerted by the different tested
oxysterols on HSV-1 infected Vero cells. The different oxysterols were added to cell
monolayers at a final concentration of 5 μM, before viral inoculum (Panels A, B) or after
viral inoculum (Panel C). See also methods for details. Panel A: percent of plaque areas
measured in Vero cells 16 h pretreated with oxysterols then infected with HSV-1, taking
the plaque area measured in infected but untreated cells as 100%. Values are means of
three different experiments (15–20 measurements/experiment). Panel B: viral yield
reduction in cells pretreated with oxysterols for 16 h and then infected. Panel C: viral
yield reduction in cell culture infected with HSV-1 and then treated with the different
oxysterols. * p<0.05**, p< 0.01***, p< 0.005.
Table 2
Viral yield reduction by 25HC and 27HC.
Cell line Compound EC50 (µM) – 95% C.I. CC50 (µM) SI
Vero 25HC 0.176 (0.124–0.250) 77.59 440.8
27HC 0.220 (0.092–0.524) > 150 >681.8
HeLa 25HC 0.257 (0.206–0.321) > 150 >583.6
27HC 0.984 (0.793–1.22) > 150 >152.4
EC50: half maximal effective concentration; C.I. confidence interval; CC50: half maximal
cytotoxic concentration; SI: selectivity index.
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Fig. 2. Intracellular recovery of 25HC and 27HC externally added to HeLa cell
incubation medium. Percent values were calculated as to the total amount added to the
medium and were determined by mass-spectrometry at 18 h, 72 h and 96 h after
oxysterols’ addition.
Fig. 3. Effect of oxysterols on IL-6 secretion by HeLa cells infected with HSV-1. The
concentration of IL-6 was measured by ELISA in culture medium of HeLa cells treated or
not with 5 μM 25HC or 5 μM 27HC (24 h), with or without HSV-1 cell infection (24 h).
Data are means of four experiments± SD. Statistical difference within experimental
groups was calculated using ANOVA associated with the Bonferroni post-test.
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transcription factor NF-kB in the expression of IL-6 and the already
demonstrated ability of certain viruses to up-regulate, at least transi-
ently, this transcription peptide's activity [22–24], the effect of the two
oxysterols ±HSV-1 infection on the p65 component of NF-kB dimer
was investigated using a confocal microscopy approach in a standard in
vitro model system for HSV-1 infection, i.e. Vero cells.(Fig. 4).
While in untreated cells immunofluorescence detection showed p65
as essentially localized in the cytoplasm, a modest increase of fluores-
cence was observed in cells pretreated with 25HC or 27HC, but a much
more evident trend to nuclear localization was evident in HSV-1
infected cells. Importantly, when cell infection was anticipated by
oxysterol treatment, an even stronger fluorescence was detectable,
especially when 25HC was employed.
3.5. Antiviral activity of IL-6
With the aim to verify if IL-6 up-regulation is actually one of the
mechanisms by which 25HC and 27HC exert antiviral effect, HeLa cells
were infected with HSV-1, then different cytokine concentrations were
added to the cell incubation medium. At the end of the experiment, a
viral yield reduction assay was performed. A dose-dependent inhibition
of HSV-1 cell infection was observed, with a statistically significant
reduction of viral titer at 100 nM and 50 nM IL-6 concentration (Fig. 5).
Of note, cell viability assayed in IL-6 treated but not infected cells
excluded that the observed IL-6 antiviral activity was a consequence of
cytotoxic or antiproliferative effects (data not shown).
4. Discussion
Oxysterols are known pleiotropic molecules, and over the last years,
antiviral properties have been attributed to this class of compounds.
However, analyzing the work done so far in this relation, there are two
main limitations. First, mechanistic studies of their potential antiviral
effects mainly focused on 25 HC due to the induction of the synthetizing
enzyme (CH25H) by IFN, while oxysterols’family is broad and var-
iegate. Second, although the pro-inflammatory activity of several
oxysterols is well known, to our knowledge, the possible interplay
between pro-inflammatory and antiviral mechanisms of action has not
been investigated yet.
To contribute to overcome these restraints, HSV-1 infection was
here chosen as a model because of the demonstrated antiviral cytokine
reaction triggered in targeted cells by the virus itself [4,13–16].
As reported in Table 1 and Fig. 1, 25HC and 27HC were the only
oxysterols, among the tested, able to dose-dependently reduce the
plaque formation, while all of them reduced plaque size and the viral
yield both in pre-treatment and post-treatment conditions, although to
different extents These findings point to possible additional mechan-
Fig. 4. Effect of oxysterols on p65 expression and nuclear translocation in Vero cells treated with oxysterols and infected with HSV-1. Vero cells were treated or not with 5 μM
25HC or 5 μM 27HC (16 h), subsequently infected or not with HSV-1 (24 h) and then subjected to immunofluorescence. Green Fluorescence was detected by using a confocal microscope
Zeiss LSM 510 with a 20×/0.5 plan neofluar lens. Images were elaborated with Zeiss LSM 510 Image Examiner processing software.
Fig. 5. Antiviral activity of IL-6. The graph shows the reduction of viral titer in presence
of different concentration of IL-6. The cells were infected with HSV-1 (MOI 1) and then
treated with different doses of IL-6; 24 h post infection, cells and supernatants were
harvested and subsequently titrated. Bars are the % of infection calculated in comparison
with untreated control. The experiment was performed three times in triplicated wells. **
p< 0.01, *** p<0.005.
V. Cagno et al. Redox Biology 12 (2017) 522–527
526
isms of action by side chain oxysterols, beside the entry inhibition
mechanism suggested by Blanc et al. [5]. 25HC was reported to have
the property to modify the composition of membranes, therefore it was
suggested to broadly inhibit enveloped viruses by alteration of fusion,
and adenoviruses were used as non enveloped control viruses to support
this hypothesis. However, some reports suggest that 25HC is effective
also against non enveloped viruses, such as poliovirus and rhinovirus
through an inhibition of the assembly of viral replication machinery
[7], supporting the possibility that the antiviral action of 25HC is linked
to different mechanisms of action.
This is most likely the first report showing an anti-HSV-1 effect of
oxysterols other than 25HC, all being of pathophysiological relevance,
and certainly the first one emphasizing the remarkable antiviral action
of 27HC in both preventing and stopping HSV-1 infection, at least in in
vitro standard tests.
Since 25HC and 27HC were shown to be by far the most active
oxysterols in inhibiting HSV-1 also in post infection tests, and in
different cell lines (Fig. 1C and Table 2), deeper investigation of
possible interrelationship between their inflammatory and antiviral
features was then performed.
But before that, it is important to remark that the concentrations of
25HC and 27HC recovered within cells were comparable (27HC) or
close (25HC) to those physiologically recovered in human plasma
[22,23]. Cell supplementation with 27HC resulted to be less efficient
than that with 25HC (Fig. 2), due to reduced entry and/or persistence
within cell, any way a likely explanation of the 27HC slightly minor
antiviral efficacy observed in comparison with 25HC. Further, the
intracellular levels of both oxysterols were quite maintained at 96 h
post treatment, suggesting long-term effects of the two molecules.
With regard to NF-kB activation, a number of viruses were shown to
trigger and up-regulate the NF-kB pathway in the infected cells, most
often at the onset of the infection process and in a transient way
[24–26]. Although such an activation might be exploited by some
viruses to enhance specific steps of their replicative cycles, it certainly
represents an alarm signaling priming a cascade of defense reactions by
the invaded cells. In this relation, a large bulk of literature points to NF-
kB dependent cellular overproduction and secretion of inflammatory
cytokines, in particular IL-6, as able to antagonize viral replication
[17–19]. However, in the long run, viruses tend to build up a variety of
immune based avoidance strategies able to by-pass or even down-
regulate the previously enhanced NF-kB transcriptional pathway
[27,28]. Still, a suitable boosting of the initial inflammatory reaction
by cells under viral attack does represent a valid tool to more efficiently
fight the infection itself.
Indeed, oxysterols of enzymatic origin, like 25HC and 27HC, whose
pro-inflammatory properties are well recognized [1,29] would appear
as potential physiological modulators of innate and acquired immune
system in fighting viral infections. The here reported additive interac-
tion between 25HC/27HC and HSV-1 in up-regulating IL-6 cellular
levels (Fig. 3) is an interesting and new example of fine interplay
between cholesterol metabolism and immune/inflammatory response
to xenobiotics.
Such an additive interaction between HSV-1 virus and 25HC or
27HC in boostering IL-6 production and secretion by the infected cells
could contribute to the observed antiviral effect exerted by the two side
chain oxysterols. This hypothesis is supported by the dose-dependent
inhibition of HSV-1replication induced by IL-6 concentrations compa-
tible with those detected in HeLa cells pretreated with 25HC or 27HC
then infected with the virus (Fig. 5).
In conclusion, 25HC and 27HC, the two oxysterols most considered
for their potential involvement in the pathophysiological tuning of
innate and acquired immune reactions, including inflammation, were
for the first time demonstrated, in the in vitro standard model system, to
be provided with strong inhibiting but also preventing effect against
HSV-1 infection. Several are most likely the mechanisms underlying
such a striking effect, being certainly included the reinforcing of IL-6
mediated restraining of viral replication and spreading.
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